European Commission Approved Celltrion Healthcare’s Bevacizumab Biosimilar

The European Commission (EC) has approved Vegzelma (CT-P16), a biosimilar to bevacizumab referencing Avastin, developed by Celltrion Healthcare. Celltrion Healthcare has announced that, the European Commission (EC) has approved Vegzelma (CT-P16), its biosimilar to be bevacizumab, referencing the Avastin approved by the European Union (EU). This European approval covers the use of Vegzelma in the […]

Continue Reading

US FDA Approves Bayer’s Darolutamide to Treat Metastatic HSPC

The US health agency approved Darolutamide, developed by Bayer, to treat patients with metastatic hormone-sensitive prostate cancer (HSPC). Darolutamide can be given alongside docetaxel plus androgen deprivation therapy (ADT). The efficacy of Darolutamide in the patients was demonstrated in the phase 2 trial. in particularly, use of Darolutamide despite placebo in combination with docetaxel plus […]

Continue Reading